^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoplasmacytic Lymphoma

    Related cancers:
    21h
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    7d
    ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Shayna Sarosiek, MD | Recruiting --> Active, not recruiting | N=33 --> 12
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    7d
    ECWM-2: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Christian Buske | Trial completion date: Sep 2029 --> Feb 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib
    7d
    Solitary Hepatic Plasmacytoma With IgM Monoclonal Gammopathy: A Case Report. (PubMed, Case Rep Hematol)
    The patient demonstrated excellent clinical and radiographic response to zanubrutinib therapy by way of improvement in IgM and the size of the liver mass...To our knowledge, this represents one of the few documented cases of IgM-secreting solitary hepatic plasmacytoma. This case highlights diagnostic challenges, the importance of immunophenotypic profiling, and the need for individualized management strategies in this rare entity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PAX5 (Paired Box 5) • SDC1 (Syndecan 1)
    |
    Brukinsa (zanubrutinib)
    8d
    BELLWAVE-003: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (clinicaltrials.gov)
    P2, N=490, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    TP53 mutation • Chr t(11;14)
    |
    nemtabrutinib (MK-1026)
    8d
    Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia. (PubMed, Haematologica)
    Not available.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    10d
    ZBR in WM: A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
    16d
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    16d
    A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia (clinicaltrials.gov)
    P4, N=18, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib)
    17d
    This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, ModeX Therapeutics, An OPKO Health Company
    New P1/2 trial
    17d
    S2005: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov)
    P2, N=92, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    18d
    BGB-11417-203: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia (clinicaltrials.gov)
    P2, N=114, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)